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ABSTRACT
The potency of the immune response has still to be
harnessed effectively to combat human cancers.
However, the discovery of T-cell targets in melano-
mas and other tumors has raised the possibility that
cancer vaccines can be used to induce a therapeu-
tically effective immune response against cancer.
The targets, cancer-testis (CT) antigens, are immu-
nogenic proteins preferentially expressed in normal
gametogenic tissues and different histological types
of tumors. Therapeutic cancer vaccines directed
against CT antigens are currently in late-stage clin-
ical trials testing whether they can delay or prevent
recurrence of lung cancer and melanoma following
surgical removal of primary tumors. CT antigens
constitute a large, but ill-defined, family of proteins
that exhibit a remarkably restricted expression.
Currently, there is a considerable amount of infor-
mation about these proteins, but the data are scat-
tered through the literature and in several
bioinformatic databases. The database presented
here, CTdatabase (http://www.cta.lncc.br), unifies
this knowledge to facilitate both the mining of the
existing deluge of data, and the identification of pro-
teins alleged to be CT antigens, but that do not have
their characteristic restricted expression pattern.
CTdatabase is more than a repository of CT antigen
data, since all the available information was care-
fully curated and annotated with most data being
specifically processed for CT antigens and stored
locally. Starting from a compilation of known CT
antigens, CTdatabase provides basic information
including gene names and aliases, RefSeq acces-
sion numbers, genomic location, known splicing
variants, gene duplications and additional family
members. Gene expression at the mRNA level in
normal and tumor tissues has been collated from
publicly available data obtained by several different
technologies. Manually curated data related to
mRNA and protein expression, and antigen-specific
immune responses in cancer patients are also avail-
able, together with links to PubMed for relevant CT
antigen articles.
INTRODUCTION
More than 11 million people are diagnosed with cancer
every year causing 12.5% of all deaths worldwide (World
Health Organization, 2006). Novel forms of cancer treat-
ment are desperately needed, and immunotherapy repre-
sents an approach that has yet to be fully explored. One
form of immunotherapy is the therapeutic cancer vaccine
that induces the immune response to recognize and
destroy cancer cells. Such vaccines can be based on speciﬁc
antigens, such as the CT antigens that are speciﬁcally
expressed in tumors with limited expression elsewhere in
the patient’s tissues. Advanced clinical trials of CT anti-
gens are underway. In 2007, GlaxoSmithKline initiated
the largest-ever lung cancer trial to test the ability of a
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therapeutic vaccine based on a CT antigen to delay the
recurrence of resected non-small cell lung cancer (1). A
second CT antigen vaccine is currently in an international
phase II clinical trial for patients with resected malignant
melanoma (2).
The ﬁrst cancer antigen was cloned from the cells of a
melanoma patient, by Thierry Boon and his colleagues (3).
The antigen in question was denominated melanoma anti-
gen-1, or MAGE-1, and subsequently renamed as MAGE-
A1. An international eﬀort to discover additional cancer
antigens soon revealed an entire family expressed only in
tumors and in the immunoprivileged gametogenic tissues.
This group was collectively termed the CT antigens by Old
and Chen (4). There are now more than 70 CT gene
families, many of them promising vaccine candidates.
Nevertheless, the range of discovery programs that have
diversely reported these important therapeutic candidates
have resulted in the terminology of a CT antigen being
loosely deﬁned and applied, adding to importance of a
single carefully curated database to be able to accurately
assess the relevance of individual proteins.
Due to their importance, there is a rapidly expanding
body of knowledge concerning these genes widely in the
literature and diverse databases. To gather and uniformly
present the available information on CT antigens, we have
created a user-friendly interface termed the Cancer-Testis
database (CTdatabase). The database integrates hetero-
geneous data including basic gene, protein and expression
information in normal and tumor tissues as well as immu-
nogenicity in cancer patients. The CTdatabase contains
links to external databases although a priority has been
to speciﬁcally process relevant data so that it can be stored
locally. The information available was expertly curated
and annotated, and regular updates are planned.
CT ANTIGENS PRESENT IN THE DATABASE
A list of CT antigens was ﬁrst compiled manually from the
literature (see references used to compile the list at http://
www.cta.lncc.br, under the link ‘Gene annotations’ in the
main page). Computational prediction was also used. The
resultant CTdatabase comprises 204 genes.
The CTdatabase has a straightforward interface where
information for individual genes and their products is dis-
played. Each entry is listed according to the oﬃcial gene
symbol (or the name available at NCBI’ Gene Entrez
database) and information is further sorted into
‘domains’, displayed as ‘tabs’ by subject: Summary,
Gene, Protein, mRNA expression, protein expression,
immune response, PubMed. The domains have been popu-
lated using automatic recovery from public databases,
manual annotation and novel data generated by RT-PCR.
THE ‘GENE’ AND ‘PROTEIN’ TABS
The ‘Gene’ tab contains general information extracted
from NCBI Entrez Gene database including aliases,
mRNA RefSeq accession numbers (5), gene structure,
chromosomal localization, exon-intron structure, RefSeq
splicing variants as well as links to the genome browsers
MapViewer (6), UCSC Genome Browser (7) and Single
Nucleotide Polymorphisms (6), where available.
The annotations extracted from NCBI Entrez Gene
were manually curated. For example, the transcripts for
SPANXE and SPANXD were found to align to a single
locus. Both entries are available in the CTdatabase, but a
warning is displayed for SPANXE indicating that this
gene is identical to SPANXD and the user is thus directed
to the SPANXD entry. Likewise, some aliases were also
corrected, for example, MAGE-A4 and MAGE-A5 are
diﬀerent genes, but NCBI Entrez Gene reports MAGE-
A4 as an alias for MAGE-A5 (as of July, 2008). The
CTdatabase also annotated gene names as splicing var-
iants when they aligned to a single genomic locus, as is
the case of LAGE-1A and LAGE-1B which are variants
of CTAG2, or SSX2B and SSX2A which are variants
of SSX2.
Careful inspection of CT gene mRNA alignments
revealed that 66 are virtually identical copies of each
other, i.e. the mRNAs align with the same identity level
to more than one locus (14 distinct genes, see website’s
link ‘Gene annotations’). This information is available in
the CTdatabase within the section termed ‘Gene copies’
under the ‘Gene’ tab.
In addition to nearly identical gene copies, many CT
antigen genes have a common evolutionary origin. We
grouped genes with >40% sequence identity as belonging
to the same family [blastp (8), E-value <0.001, complexity
ﬁlter oﬀ and percent identity normalized for alignment
length as % identity  alignment length/length of the
shorter protein]. This analysis resulted in 12 groups:
CSAG, CT45, CT47, CTAG, CTAGE, GAGE, MAGE,
NXF, SPANX, SSX, TSPY, XAGE1.
Using these groups as a guide, multiple alignments
(non-edited) were made with Clustalx (9). Phylogenetic
trees were inferred with the program MEGA 3 (10)
using neighbor joining, pair wise deletion, JTT matrix
and bootstrapping 100 times. The sub-families thus iden-
tiﬁed are reported in the ‘Gene’ tab under the section
‘Phylogenetic relationships with CT genes’. Note that
the family information provided by the CTdatabase is a
ﬁrst approach and should be used with caution.
As with the ‘Gene’ tab, the ‘Protein’ tab also contributes
general information on the protein products of CTgenes,
such as RefSeq accession numbers, names [from UniProt,
(11)], and known protein domains. It also contains manu-
ally annotated sections on protein–protein interactions,
protein localization and protein function.
THE ‘mRNA Expression’ Tab
CT antigens (or candidate CT antigens) were classiﬁed
according to their expression patterns. Based on a collec-
tive analysis of data from CAGE, MPSS, RT-PCR and
ESTs (see website for details), genes are considered to be:
(a) testis-restricted, (b) testis/brain-restricted, or (c) testis-
selective (Annotation ﬁeld: ‘Gene expression pattern’).
Since the principal importance of CT antigens lies in
their restricted expression in normal tissues and ample
expression in cancers, a central feature of the
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CTdatabase is mRNA expression data. These data are
divided between ‘High-throughput’ (obtained using
large-scale techniques), ‘Tested by Ludwig Institute for
Cancer Research’ (RT-PCR) and ‘Published literature’
(manual annotation).
HIGH-THROUGHPUT DATA
Three diﬀerent sources of data were utilized: Serial
Analysis of Gene Expression [SAGE, (12)], Massive
Parallel Signature Sequencing [MPSS, (13)] and
Expressed Sequence Tags [EST, (14)].
ESTs are cDNA fragments of a hundred or more
nucleotides (nt). SAGE data are comprised of ‘short’ or
‘long’ sequence tags, 10 nt and 17 nt, respectively, from the
30-end of mRNAs. Massive Parallel Signature Sequencing
tags are 13 nt tags obtained using an alternative sequenc-
ing protocol. In all cases, the number of EST, SAGE or
MPSS tags reﬂect the number of mRNA copies in a cell;
the higher the number of tags observed for a given gene,
the higher the expression of the gene. The CTdatabase
contains a heat map of color-coded expression levels of
CT antigens. Genes not conﬁrmed as CT antigens have
their expression levels presented in the heat map, but are
ﬂagged as not being testis restricted.
SAGE AND MPSS
Both SAGE and MPSS tags are computationally pre-
dicted for each CT gene (mRNA RefSeq) using custom
programs that simulate the SAGE/MPSS protocols. To do
this, we located the 30 most CATG site (the enzyme cleav-
age site used for SAGE) or GATC (the cleavage site used
for MPSS) and extracted the putative downstream tag. To
guarantee that the tag is derived from the 30-end of a given
CT antigen only mRNAs with a poly-A tail (>5 As)
are used.
When a given tag is observed in more than one gene, it
is not accepted as a bona-ﬁde tag. When the tag belongs to
gene copies, a warning is displayed, cautioning the user
that the expression level may not be correctly reported.
The frequency of each predicted tag (expression level) in
diﬀerent tissues was downloaded from SAGE Genie (15)
at the Ludwig Institute for Cancer Research (LICR) FTP
site (ftp://ftp.licr.org/pub/databases/trome/human/) and
parsed to generate a heat map. Only tissues with
more than 100 000 tags are shown. Library annotation
(normal/cancer, sample source, etc) were downloaded
from SAGE Genie. A limited number of corrections
were manually performed.
ESTs
The number of ESTs per gene contained in UniGene clus-
ters with at least 60 000 sequences were normalized per
million and also presented as a heat map. Tissue and
health state annotation provided by UniGene were used
to separate the cancer libraries presented. Normalized and
subtracted libraries were excluded from the data to avoid
sampling biases. Intronless ESTs were excluded to avoid
bias from genomic DNA contaminations.
Some CT antigen genes had more than one correspond-
ing UniGene cluster due to gene copies. For these cases,
UniGene clusters were merged following manual inspec-
tion and a corresponding warning is displayed in
the entry.
RT-PCR
In addition to third-party expression data, the
CTdatabase provides an RT-PCR analysis of the expres-
sion levels of all CT antigen genes. A standardized analysis
was undertaken in the same set of cDNA preparations
from normal human tissues as well as selected human
cancer cell lines. Thus the expression of 106 genes was
analyzed in a panel of 22 normal tissues and 34 cancer
cell lines by RT-PCR at the LICR New York Branch.
Gel images are displayed and the experimental conditions,
including primer sequences, PCR cycles and temperatures
are provided.
LITERATURE DATA
Manually curated information retrieved from the litera-
ture is included in the CTdatabase. A list of normal tissues
expressing the referred CT, as indicated by literature refer-
ences, is shown. Data on expression of individual CT anti-
gens in neoplasias were annotated and are presented
according to tumor type and subtype, indicating the
level of expression. A list of cell lines expressing each
CT gene is also presented. For all literature information,
the experimental method is provided as well as links to the
PubMed references.
THE ‘PROTEIN EXPRESSION’ TAB
The protein expression tab includes manually reviewed
information from the literature on CT protein expression
in normal tissues, tumor tissues and tumor cell lines. The
methodologies employed in the experiments and the
PubMed references are provided. A list of antibodies
raised against CT antigens as published in the literature
is included.
THE ‘IMMUNE RESPONSE’ AND ‘PubMed’ TABS
The ‘Immune response’ tab is divided into three sections
containing information manually curated from the litera-
ture respectively focused on ‘Humoral immune response’,
‘Cellular immune response’ and ‘Induced immune
response’. The ﬁrst section contains data on spontaneous
humoral immune responses to CT antigens in patients
with diﬀerent tumor types, including the frequency of
patients with antibodies against the antigen where avail-
able. The technique used for detection of the antibodies
and the PubMed article reference is shown for each entry.
The ‘Cellular immune response’ section contains informa-
tion on spontaneous cellular immune responses against
the CT antigen in cancer patients. This tab also displays
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a table listing the peptides recognized by T cells
extracted from the database at http://www.cancerimmun
ity.org/peptidedatabase/tumorspeciﬁc.htm. The ‘Induced
immune response’ section lists the results, with links to
PubMed, from published clinical trials in which cancer
patients received CT antigen-based vaccines.
Finally, the tab ‘PubMed’ hosts all the references
related to individual gene entries.
IMPLEMENTATION
CTdatabase runs on free software (MySQL database
server, Apache WWW server with the interface written
in PHP). Perl and shell scripts were written to parse down-
loaded data.
FUTURE DIRECTIONS
Most of the work done on CT antigens has focused on the
immunologic aspects of this intriguing family of proteins.
However, a central question that remains to be answered
is whether CT antigen expression contributes to tumori-
genesis or is a functionally irrelevant by-product of the
process of cellular transformation. Initial structural and
functional information on CT antigens indicate that CT
antigen expression could have a fundamental role in
human tumorigenesis. Knowledge on diﬀerent aspects of
CT antigens is continuously expanding and we plan
to update the CTdatabase structure by adding new infor-
mation as it appears in the literature. In addition, the
high-throughput data will also be upgraded periodically.
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